277 related articles for article (PubMed ID: 28560655)
1. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.
Thomson CA; Chow HHS; Wertheim BC; Roe DJ; Stopeck A; Maskarinec G; Altbach M; Chalasani P; Huang C; Strom MB; Galons JP; Thompson PA
Breast Cancer Res Treat; 2017 Aug; 165(1):97-107. PubMed ID: 28560655
[TBL] [Abstract][Full Text] [Related]
2. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer.
Dalessandri KM; Firestone GL; Fitch MD; Bradlow HL; Bjeldanes LF
Nutr Cancer; 2004; 50(2):161-7. PubMed ID: 15623462
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense
Green T; See J; Schauch M; Reil J; Glover M; Brix J; Gerry A; Li K; Newman M; Gahler RJ; Wood S
J Complement Integr Med; 2023 Mar; 20(1):199-206. PubMed ID: 36201753
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.
Gee JR; Saltzstein DR; Messing E; Kim K; Kolesar J; Huang W; Havighurst TC; Harris L; Wollmer BW; Jarrard D; House M; Parnes H; Bailey HH
Eur J Cancer Prev; 2016 Jul; 25(4):312-20. PubMed ID: 26313229
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
6. The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers.
Nikitina D; Llacuachaqui M; Sepkovic D; Bradlow HL; Narod SA; Kotsopoulos J
Fam Cancer; 2015 Jun; 14(2):281-6. PubMed ID: 25613194
[TBL] [Abstract][Full Text] [Related]
7. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
[TBL] [Abstract][Full Text] [Related]
8. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women.
Ursin G; London S; Yang D; Tseng CC; Pike MC; Bernstein L; Stanczyk FZ; Gentzschein E
Breast Cancer Res Treat; 2002 Mar; 72(2):139-43. PubMed ID: 12038704
[TBL] [Abstract][Full Text] [Related]
9. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk.
Ho GH; Luo XW; Ji CY; Foo SC; Ng EH
Ann Acad Med Singap; 1998 Mar; 27(2):294-9. PubMed ID: 9663330
[TBL] [Abstract][Full Text] [Related]
10. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
Kroiss R; Fentiman IS; Helmond FA; Rymer J; Foidart JM; Bundred N; Mol-Arts M; Kubista E
BJOG; 2005 Feb; 112(2):228-33. PubMed ID: 15663589
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.
Serrano D; Lazzeroni M; Gandini S; Macis D; Johansson H; Gjerde J; Lien E; Feroce I; Pruneri G; Sandri M; Bassi F; Brenelli F; Luini A; Cazzaniga M; Varricchio C; Guerrieri-Gonzaga A; DeCensi A; Bonanni B
Breast Cancer Res; 2013 Jun; 15(3):R47. PubMed ID: 23786776
[TBL] [Abstract][Full Text] [Related]
12. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.
Ursin G; London S; Stanczyk FZ; Gentzschein E; Paganini-Hill A; Ross RK; Pike MC
J Natl Cancer Inst; 1999 Jun; 91(12):1067-72. PubMed ID: 10379970
[TBL] [Abstract][Full Text] [Related]
13. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Ellmén J; Hakulinen P; Partanen A; Hayes DF
Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
[TBL] [Abstract][Full Text] [Related]
14. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
15. [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer].
Sommer H; Pröhl-Steimer B; Bajetta E; Haus U; Janni W; Kay A
Zentralbl Gynakol; 2001 Oct; 123(10):557-61. PubMed ID: 11753809
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.
Ursin G; London S; Stanczyk FZ; Gentzschein E; Paganini-Hill A; Ross RK; Pike MC
Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):601-5. PubMed ID: 9168002
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
18. Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data.
Dallal CM; Stone RA; Cauley JA; Ness RB; Vogel VG; Fentiman IS; Fowke JH; Krogh V; Loft S; Meilahn EN; Muti P; Olsen A; Overvad K; Sieri S; Tjønneland A; Ursin G; Wellejus A; Taioli E
Int J Biol Markers; 2013 Apr; 28(1):3-16. PubMed ID: 22865302
[TBL] [Abstract][Full Text] [Related]
19. Circulating estrogen metabolites and risk of breast cancer in postmenopausal women.
Arslan AA; Koenig KL; Lenner P; Afanasyeva Y; Shore RE; Chen Y; Lundin E; Toniolo P; Hallmans G; Zeleniuch-Jacquotte A
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1290-7. PubMed ID: 24769889
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
